Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
GSK and ViiV Healthcare’s pre-exposure prophylaxis drug Apretude is more than 99% effective at preventing HIV infections, according to real-world results being presented at this week’s IDWeek 2024 conference.
The results came from the real-world OPERA and Trio Health cohorts, which together enrolled almost 1,300 individuals, and “support the strong and sustained effectiveness of Apretude … outside the controlled environment of a clinical trial,” ViiV CMO Harmony Garges said in a statement. These data “add to the growing body of evidence generated over the last three years, showing [Apretude] for PrEP is a highly effective option for HIV prevention.”